These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35912746)

  • 1. Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis.
    Kong Y; Chen Z; Wang X; Wang W; Zhang J
    J Alzheimers Dis; 2022; 89(2):493-503. PubMed ID: 35912746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.
    Llorens F; Kruse N; Schmitz M; Gotzmann N; Golanska E; Thüne K; Zejneli O; Kanata E; Knipper T; Cramm M; Lange P; Zafar S; Sikorska B; Liberski PP; Mitrova E; Varges D; Schmidt C; Sklaviadis T; Mollenhauer B; Zerr I
    Alzheimers Dement; 2017 Jun; 13(6):710-719. PubMed ID: 27870938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.
    Llorens F; Kruse N; Karch A; Schmitz M; Zafar S; Gotzmann N; Sun T; Köchy S; Knipper T; Cramm M; Golanska E; Sikorska B; Liberski PP; Sánchez-Valle R; Fischer A; Mollenhauer B; Zerr I
    Mol Neurobiol; 2018 Mar; 55(3):2249-2257. PubMed ID: 28321768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease.
    Llorens F; Zafar S; Ansoleaga B; Shafiq M; Blanco R; Carmona M; Grau-Rivera O; Nos C; Gelpí E; Del Río JA; Zerr I; Ferrer I
    Neuropathol Appl Neurobiol; 2015 Aug; 41(5):631-45. PubMed ID: 25134744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach.
    Lee SM; Hyeon JW; Kim SJ; Kim H; Noh R; Kim S; Lee YS; Kim SY
    Prion; 2019 Jan; 13(1):141-150. PubMed ID: 31306078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
    Kasai T; Tokuda T; Ishii R; Ishigami N; Tsuboi Y; Nakagawa M; Mizuno T; El-Agnaf OM
    J Neurol; 2014 Jun; 261(6):1203-9. PubMed ID: 24737170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.
    Oeckl P; Metzger F; Nagl M; von Arnim CA; Halbgebauer S; Steinacker P; Ludolph AC; Otto M
    Mol Cell Proteomics; 2016 Oct; 15(10):3126-3138. PubMed ID: 27507836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.
    Lattanzio F; Abu-Rumeileh S; Franceschini A; Kai H; Amore G; Poggiolini I; Rossi M; Baiardi S; McGuire L; Ladogana A; Pocchiari M; Green A; Capellari S; Parchi P
    Acta Neuropathol; 2017 Apr; 133(4):559-578. PubMed ID: 28205010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias.
    Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Polischi B; Capellari S; Parchi P
    Alzheimers Res Ther; 2023 Sep; 15(1):150. PubMed ID: 37684653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice.
    Fayolle M; Lehmann S; Delaby C
    J Neural Transm (Vienna); 2022 Feb; 129(2):133-139. PubMed ID: 35041062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases.
    Schmitz M; Villar-Piqué A; Hermann P; Escaramís G; Calero M; Chen C; Kruse N; Cramm M; Golanska E; Sikorska B; Liberski PP; Pocchiari M; Lange P; Stehmann C; Sarros S; Martí E; Baldeiras I; Santana I; Žáková D; Mitrová E; Dong XP; Collins S; Poleggi A; Ladogana A; Mollenhauer B; Kovacs GG; Geschwind MD; Sánchez-Valle R; Zerr I; Llorens F
    Brain; 2022 Apr; 145(2):700-712. PubMed ID: 35288744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.
    Dorey A; Tholance Y; Vighetto A; Perret-Liaudet A; Lachman I; Krolak-Salmon P; Wagner U; Struyfs H; De Deyn PP; El-Moualij B; Zorzi W; Meyronet D; Streichenberger N; Engelborghs S; Kovacs GG; Quadrio I
    JAMA Neurol; 2015 Mar; 72(3):267-75. PubMed ID: 25559883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt-Jakob disease: a comparative prospective study with 14-3-3.
    Llorens F; Villar-Piqué A; Hermann P; Schmitz M; Goebel S; Waniek K; Lachmann I; Zerr I
    J Neurol; 2020 Feb; 267(2):543-550. PubMed ID: 31701333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.
    Schmitz M; Villar-Piqué A; Llorens F; Gmitterová K; Hermann P; Varges D; Zafar S; Lingor P; Vanderstichele H; Demeyer L; Stoops E; Trojanowski JQ; Lee VM; Zerr I
    Mol Neurobiol; 2019 May; 56(5):3476-3483. PubMed ID: 30136097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
    Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
    Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders.
    Singh A; Beveridge AJ; Singh N
    PLoS One; 2011 Mar; 6(3):e16804. PubMed ID: 21408069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.
    Hermann P; Haller P; Goebel S; Bunck T; Schmidt C; Wiltfang J; Zerr I
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.
    Koscova S; Zakova Slivarichova D; Tomeckova I; Melicherova K; Stelzer M; Janakova A; Kosorinova D; Belay G; Mitrova E
    Mol Neurobiol; 2017 Oct; 54(8):5919-5927. PubMed ID: 27665282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.